Brain tissue loss tracks thinking and disability in MS
By MS Buddy ·
Summarized from Molecular psychiatry, Apr 2023 · PubMed · DOI. AI-generated summary. Not medical advice.
Observational study · 458 people with and without MS
Research by Alessia Fiore, Massimo Filippi and 7 colleagues at IRCCS San Raffaele Scientific Institute in Italy.
How does brain tissue loss relate to disability and thinking problems in MS?
Key Takeaway
In MS, patterns of brain tissue loss were linked to disability and thinking problems.

What They Found
Brain scans showed more widespread tissue loss in people with MS than in people without MS. Researchers compared the affected areas with maps showing where different brain chemicals act. People with longer-lasting MS or greater disability had tissue loss in areas linked to certain brain chemicals. People with thinking problems also had widespread tissue loss linked to several chemical maps. People with fatigue had tissue loss, but it did not match the chemical maps; no such link was found for depression.
Who Should Care and Why
The study included people with MS and people without MS. It examined how brain tissue loss differed between these groups. Among people with MS, it also compared those with different levels of disability. The researchers looked separately at thinking problems, fatigue, and depression. The findings describe patterns seen on scans, not what caused those patterns.
Important Considerations
You should know this was a comparison of brain scans and health assessments, not a treatment test. It included 286 people with MS and 172 people without MS. These links cannot show whether brain chemicals caused tissue loss or symptoms.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Molecular psychiatry by et al.. Reproduced from the PubMed record.
In multiple sclerosis (MS), gray matter (GM) atrophy progresses in a non-random manner, possibly in regions with a high distribution of specific neurotransmitters involved in several relevant central nervous system functions. We investigated the associations among regional GM atrophy, atlas-based neurotransmitter distributions and clinical manifestations in a large MS patients' group. Brain 3 T MRI scans, neurological examinations and neuropsychological evaluations were obtained from 286 MS patients and 172 healthy controls (HC). Spatial correlations among regional GM volume differences and atlas-based nuclear imaging-derived neurotransmitter maps, and their associations with MS clinical features were investigated using voxel-based morphometry and JuSpace toolbox. Compared to HC, MS patients showed widespread GM atrophy being spatially correlated with the majority of neurotransmitter maps (false discovery rate [FDR]-p ≤ 0.004). Patients with a disease duration ≥ 5 vs < 5 years had significant cortical, subcortical and cerebellar atrophy, being spatially correlated with a higher distribution of serotoninergic and dopaminergic receptors (FDR-p ≤ 0.03). Compared to mildly-disabled patients, those with Expanded Disability Status Scale ≥ 3.0 or ≥ 4.0 had significant cortical, subcortical and cerebellar atrophy being associated with serotonergic, dopaminergic, opioid and cholinergic maps (FDR-p ≤ 0.04). Cognitively impaired vs cognitively preserved patients had widespread GM atrophy being spatially associated with serotonergic, dopaminergic, noradrenergic, cholinergic and glutamatergic maps (FDR-p ≤ 0.04). Fatigued vs non-fatigued MS patients had significant cortical, subcortical and cerebellar atrophy, not associated with neurotransmitter maps. No significant association between GM atrophy and neurotransmitter maps was found for depression. Regional GM atrophy with specific neurotransmitter systems may explain part of MS clinical manifestations, including locomotor disability, cognitive impairment and fatigue.
Categories
Explore more research
Related MS research

11/17/2026
An experimental drug eased nerve-related problems and reduced inflammation in mice with an MS-like d
Read More
11/17/2026
A review explores iron-driven cell death in MS and other diseases involving immune attacks on the bo
Read More
11/16/2026
In mice with damaged nerve coverings, fat-derived stem cells treated with metformin improved repair.
Read More
11/17/2026
Genetic and brain scan data linked inherited brain structure patterns to MS risk. Researchers also f
Read More
11/17/2026
Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ
Read More
11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
